SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Tempest Therapeutics, Inc. (TPST) (CIK 0001544227) (TPST) — Jul 17, 2012

Tempest Therapeutics, Inc. (TPST) (CIK 0001544227)
Date: July 17, 2012 · CIK: 0001544227 · Accession: 0000000000-12-037418

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

Date
April 11, 2012
Author
/s/ Jeffrey Riedler
Form
UPLOAD
Company
Tempest Therapeutics, Inc. (TPST) (CIK 0001544227)

Letter

July 17 , 2012 Via E -mail Christopher Bleck Chief Operating Officer OvaScience, Inc. 800 Boylston Street, Suite 1555 Boston, Massachusetts 02199

Re: OvaScience, Inc. Registration Statement on Form 10-12G Filed April 11, 2012 File No. 000 -54647

Dear Mr. Bleck :

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We u rge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,
/s/ Jeffrey Riedler

Show Raw Text
July 17 , 2012

Via E -mail
Christopher Bleck
Chief Operating Officer
OvaScience, Inc.
800 Boylston Street, Suite 1555
Boston, Massachusetts 02199

Re: OvaScience, Inc.
 Registration Statement on Form 10-12G
Filed April 11, 2012
File No. 000 -54647

Dear Mr. Bleck :

We have completed our review of your filing.  We remind you that our comments or
changes to disclosure in response to our comments do not foreclose the Commission from taking
any action with respect to the company or the filing and the company may not assert staff
comments as a defense in any proceeding initiated by the Commission or any person under the
federal securities laws of the United States.  We u rge all persons who are responsible for the
accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the
information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

 /s/ Jeffrey Riedler

Jeffrey Riedler
Assistant Director

cc: Lia Der Marderosian, Esq.
WilmerHale
60 State Street
Boston , MA 02109